The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A.
MECHANISM OF ACTION
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor that selectively targets Src and Abl kinases. It has minimal activity against stem cell factor receptor (c-KIT) or platelet-derived growth factor receptor (PDGFR). [1] [2] [3] [4] [5] [6] [7] [8] 
PHARMACOKINETICS
Following oral administration of a 500 mg dose, bosutinib has a maximum serum concentration (C max ) of 101.9 ng/mL to 114 ng/mL, 1,3 a time to C max (T max ) of 5 to 6 hours, 1, 3 and an area under the time versus concentration curve (AUC) of 2,064 ng•h/mL to 2,330 ng•h/mL. 1, 3 The C max and AUC increase 1.8-and 1.7fold, respectively, when the drug is given with a highfat meal. 8 Bosutinib has a volume of distribution (V d ) of 6,000 to 11,100 L, and a half-life (t1 2 ) of 13 hours to 22.27 hours. 1, 3, 4, 8 Bosutinib is metabolized in the liver, primarily by the CYP3A4 enzyme. Bosutinib's metabolites are inactive, with oxydechlorinated bosutinib (19%) and N-desmethylated bosutinib (25%) being the major metabolites. Bosutinib N-oxide is a minor metabolite. Bosutinib excretion is primarily hepatic (93%), with about 3% of the drug excreted in the urine. 8 Selected therapeutic regimens of bosutinib appear in Table 1 . 1, 4, 5, 7, 9, [11] [12] [13] (grade 3 or 4) 1% to 13%. 1,5,7,10,11,13 E. Gastrointestinal: Abdominal pain 9% to 23%, 1, 4, 5, 7, 13 (grade 3 or 4) 1% 1, 4, 7, 13 ; anorexia 13% to 38%, 1, 4, 5 (grade 3 or 4) 1% 1,5 ; constipation 11%, (grade 3 or 4) ,1% 1 ; diarrhea 17% to 93%, 1, 2, 4, 5, 7, [9] [10] [11] [12] [13] [14] [15] (grade 3 or 4) 6% to 23% 1, 4, 5, 7, [9] [10] [11] [12] [13] [14] [15] ; flatulence 7% to 31% 5 ; nausea 17% to 79%, 1, 2, 4, 5, 7, [9] [10] [11] [12] [13] 15 (grade
PREPARATION

MECHANISM OF ACTION
Regorafenib is a tyrosine kinase and vascular endothelial growth factor (VEGF) inhibitor. It inhibits tumor growth, angiogenesis, and metastasis by targeting a variety of kinases involved in oncogenes, tumor angiogenesis, and maintenance of the tumor microenvironment. Regorafenib's targets include VEGF receptors 1-3, KIT, PDGFR-a, PDGFR-b, RET, FGFR, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, SAPK2, PTK5, and Abl. [17] [18] [19] 
PHARMACOKINETICS
Regorafenib is 69% bioavailable from the oral tablet; an oral solution is reported to have a bioavailability of 83%. 20 A high-fat meal increases the mean AUC of the parent drug by 48% and decreases the mean AUC of the N-oxide and N-desmethyl metabolites by 20% and 51%, respectively. A low-fat meal increases the mean AUC of regorafenib and the N-oxide and N-desmethyl metabolites 36%, 40%, and 23%, respectively. Regorafenib has a maximum serum concentration (C max ) of 2.5 to 3.45 ng/mL, 17,20 a T max of 1 to 6 hours, 18, 20 and an AUC of 50.26 ng•h/mL to 70 ng•h/mL. 17, 20 Regorafenib is highly (99.5%) protein bound and has a half-life (t1 2 ) of 20 to 40 hours. 18, 20 Regorafenib is metabolized in the liver by CYP3A4 and UGT1A9 to 2 active metabolites: N-oxideregorafenib and N-desmethyl-regorafenib. 20 Regorfenib is excreted primarily in the feces, with 47% as unchanged drug and 24% as the metabolites. About 19% is excreted renally, 17% as metabolites. 20 The elimination half life (t1 2 ) is 28 hours. Selected therapeutic regimens of regorafenib appear in Table 2 .
PREPARATION
A. Follow institutional policies for preparation
of hazardous medications when dispensing regorafenib. B. Regorafenib is available as 40 mg tablets.
STORAGE
A. Store at controlled room temperature of 20°C to 25°C (68°F to 77°F). B. Brief exposure to temperatures from 15°C to 30°C (59°F to 86°F) is acceptable. 17, 18 ; dry skin 18% 17 ; rash, desquamation 29% to 50%, 17, 18, 21 (grade 1 or 2) 26%, 22 (grade 3) 3%, 21 (grade 3 or 4) 5% to 8% 17, 18, 28 ; rash, unspecified type (grade 3) 9% 19 ; unspecified reaction 68%, 17 (grade 3 or 4) 34%. 17 D. Gastrointestinal: Anorexia 24% to 50%, 17, 18 (grade 3) 6%, 19 (grade 3 or 4) 8% 18 ; diarrhea 21% to 60%, 17, 18, 21, 23 (grade 3) 3%, 21 (grade 3 or 4) 3% to 18% 17, 18, 23, [26] [27] [28] ; mucositis 18% to 40%, 17, 18, 23 (grade 1 or 2) 24%, 21 (grade 3 or 4) 8% 18, 23 ; nausea 25% to 40%, 23 Note: PO 5 oral. a Conforms to dosing information listed in the manufacturer's labeling.
